{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:24:36Z","timestamp":1648974276352},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/cco.0b013e3283490515","type":"journal-article","created":{"date-parts":[[2011,7,8]],"date-time":"2011-07-08T17:02:06Z","timestamp":1310144526000},"page":"449-454","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance therapy in follicular lymphoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Anne-Sophie","family":"Michallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.1998.16.7.2332","article-title":"Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe dEtude des Lymphomes Folliculaires 86 Trial.","volume":"16","author":"Solal-Celigny","year":"1998","journal-title":"J Clin Oncol"},{"key":"R2-6-20210128","first-page":"425","article-title":"Maintenance therapy for low-grade lymphomas: has the time come Curr Opin O","volume":"19","author":"Cartron","year":"2007","journal-title":"ncol"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1998.16.1.41","article-title":"Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkins lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.","volume":"16","author":"Hagenbeek","year":"1998","journal-title":"J Clin Oncol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-a study from the groupe detude des lymphomes de ladulte.","volume":"28","author":"Bachy","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma.","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent nonhodgkins lymphoma.","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 3598.","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3816\/CLM.2006.n.024","article-title":"Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).","volume":"6","author":"Kahl","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsedresistant follicular non-Hodgkins lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsedresistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase3, randomised controlled trial.","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2010.509456","article-title":"Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.","volume":"51","author":"Thompson","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkins lymphoma: a randomized trial.","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1200\/JCO.2010.29.7531","article-title":"Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.","volume":"28","author":"Niitsu","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e3283490515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:12:49Z","timestamp":1620951169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201109000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3283490515","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}